Sir, Early leprosy relapse is probably due to inadequate treatment and late relapse due to bacillary persistence or re-infection. Relapse of leprosy is an important quality of service indicators in assessing the long-term efficacy of chemotherapy, i.e., multi-drug therapy (MDT). Relapse in leprosy is compounded by irregular treatment, particularly in chronic disease. The predisposing factors for relapse include the presence of persister Bacilli, monotherapy (dapsone), inadequate or irregular therapy, the presence of multiple skin lesions and/or thickened nerves, etc. [1] After introduction of MDT for the control of leprosy, since, then, there has been a significant change in the leprosy scenario both at the global and national level, and the active case load came down drastically. Relapse rates in paucibacillary (PB) (0.65-3.0%) and multibacillary (MB) leprosy (0.02-0.8%) were estimated by various studies. [2] Reports from all over the world regarding effectiveness of MDT in MB and PB are very encouraging. However, some relapse may be and are occurring through small scale compared to the vast majority it benefits. Such relapse cases should be kept under surveillance. A 13-year-old male child was first diagnosed with PB leprosy in the year 2010. He has taken six pulses of MDT irregularly from the nearest primary health center and declared as release from treatment before reporting to our Institute.
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In July 2015, after 5 years of completion of treatment (MDT), he has noticed new fresh hypo pigmented well defined patches with loss of sensation appeared over hand, leg, face and back since 3 and half months [ Figures 1-3 ]. The patches are variable in size, flat, and brown. Patches were looking active, and margins are illdefined in nature. On examination of all peripheral nerves were not thickened or nontender. No any signs and symptoms of lepra reactions seen. He has known family contact history, i.e., grandmother, suffered from MB cases of leprosy. He was completed primary routine immunization schedule as revealed by the mother. The child underwent slit skin smear, motor, and sensory examination. Nerve function assessment was carried out by voluntary muscle testing for the function of muscles supplied by the nerve and sensory test testing for sensory loss in the areas supplied by the nerve and found normal. His slit skin smears examination shows zero bacillary index (BI) and the morphological index. He was clinically classified as a case relapse MB and put on MDT for 12 months as per WHO guidelines. A patient who has completed an adequate course of MDT, but who subsequently develops new signs and symptoms of the disease after taking a complete treatment were taken as relapse as per WHO. The insidious appearance of a new lesion or a definite increase in the size of the lesion and or appearance of new nerve thickening were noted in relapse cases. However, an increase in BI of even 2+ logs at any site over the previous BI in two successive examinations should be considered adequate supporting evidence for diagnosing relapse in patients who had earlier become negative or were showing a downward trend in BI after MDT treatment. In PB leprosy, the criteria for relapse depend primarily on clinical features since even histological examination cannot clearly distinguish between reactions and relapse. [3] The patient is residing in a locality where he was exposed to other infected patients. The duration of this dormant state may be a few months to a few years. In lepromatous leprosy case, there is impaired host cellular immune response to Mycobacterium leprae, so that a treated case of leprosy remains susceptible to re-infection even after completion of therapy. The risk is more prominent in endemic areas. [4] Patient once infected with leprosy may again be infected, if its cell-mediated immunity is low, so recurrence of disease in an MDT release after treatment case may be due to reinfection. [5, 6] The differences between relapse and reversal reaction was ruled out by clinical examination and history. In above case, the relapse occurred after completion of MDT therapy, and this could be due to irregular MDT or the multiplication of persister Bacilli or long survival of drug-sensitive persister, which might have multiplied slowly over the years after the stoppage of treatment. Hence, this is clear-cut a case of leprosy relapse. Such case report re-emphasizes that leprosy cases must be kept under clinical as well as bacteriological follow-up for as long as possible after completion of MDT regimens.
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symptomatically without further evaluation. Cutaneous examination revealed slate gray to brown pigmentation over the nose, perinasal, and perioral area. No evidence of similar pigmentation was noted anywhere else on the body. Physical evaluation and systemic examination were within normal limits. The basic hematology and blood biochemistry work up was also within normal limits. The differential diagnosis considered at this point was CKG induced pigmentation, posttraumatic (birth injury), and postinflammatory hyperpigmentation. A provisional diagnosis of CKG induced pigmentation Sir, Chikungunya (CKG), derives its name from "Kungunyala," which means "that which bends up" in Makonde language, relating to the stooped posture adopted by these patients due to incapacitating polyarthralgia or arthritis. It is caused by alphavirus and is transmitted by the Asian tiger mosquitoes, Aedes aegypti, and Aedes albopictus. The first reported outbreak of CKG in India was from Calcutta city in 1963. The mucocutaneous manifestations of the disease include facial flush, fine discrete morbilliform exanthema, and occasionally, purpura has been reported. Other reported lesions include generalized vesiculobullous eruptions, lymphedema, and intertriginous aphthous-like ulcers. [1, 2] Herein, we report a 4 days old infant with the classical chik sign with positive IgM capture ELISA specific for CKG virus with negative titers in the mother.
A 4-day-old girl child born of nonconsanguineous marriage and full term normal vaginal delivery was brought to the dermatology outpatient clinic by the parents with centrofacial pigmentation noticed since the 2 nd day of life [ Figure 1 ]. The child did not have any history of fever; there was no history of prior medications, topical application, or any significant ante natal or birth history. The mother gave history of low grade fever without any arthralgia during the 9 th month of pregnancy, which was labeled as viral fever by the physician and was managed "Chik" from the womb! 
